Clinical implication of serum Wisteria floribunda agglutinin positive Mac-2-binding protein level on hepatitis B e-antigen loss or seroconversion in hepatitis B e-antigen positive patients

Hepatology Research

Volumn 46, Issue 11, 2016, Pages 1065-1073

  Nishikawa, Hiroki ^a   Enomoto, Hirayuki ^a   Iwata, Yoshinori ^a   Kishino, Kyohei ^a   Shimono, Yoshihiro ^a   Hasegawa, Kunihiro ^a   Nakano, Chikage ^a   Takata, Ryo ^a   Nishimura, Takashi ^a   Yoh, Kazunori ^a   Ishii, Akiio ^a   Aizawa, Nobuhiro ^a   Sakai, Yoshiyuki ^a   Ikeda, Naoto ^a   Takashima, Tomoyuki ^a   Iijima, Hiroko ^a   Nishiguchi, Shuhei ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

chronic hepatitis B; hepatitis B e antigen loss; hepatitis B e antigen seroconversion; nucleoside nucleotide analog; Wisteria floribunda agglutinin positive Mac 2 binding protein

Indexed keywords

AGGLUTININ; BINDING PROTEIN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; MAC 2 BINDING PROTEIN; NUCLEOTIDE DERIVATIVE; UNCLASSIFIED DRUG; VIRUS DNA;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEROCONVERSION; WISTERIA; WISTERIA FLORIBUNDA;

EID: 84991113075     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12655     Document Type: Article

References (35)

1. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45(4): 529–38.
2. Tawada A, Kanda T, Yokosuka O. Current and future directions for treating hepatitis B virus infection. World J Hepatol 2015; 7(11): 1541–52.
3. McMahon BJ. Natural history of chronic hepatitis B. Clin Liver Dis 2010; 14: 381–96.
4. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet 2015; 386(10003): 1546–55.
5. Matsuura K, Tanaka Y, Hige S et al. Distribution of hepatitis B virus genotypes among patients with chronic infection in Japan shifting toward an increase of genotype A. J Clin Microbiol 2009; 47(5): 1476–83.
6. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008; 48: 335–52.
7. Yang HI, Lu SN, Liaw YF et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002; 347: 168–74.
8. Chen CJ, Yang HI, Iloeje UH. Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology 2009; 49: S72–84.
9. Hsu YS, Chien RN, Yeh CT et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002; 35: 1522–7.
10. Hui CK, Leung N, Shek TW et al. Sustained disease remission after spontaneous HBeAg seroconversion is associated with reduction in fibrosis progression in chronic hepatitis B Chinese patients. Hepatology 2007; 46: 690–8.
11. Liaw YF. HBeAg seroconversion as an important end point in the treatment of chronic hepatitis B. Hepatol Int 2009; 3(3): 425–33.
12. Yokosuka O, Kurosaki M, Imazeki F et al. Management of hepatitis B: Consensus of the Japan Society of Hepatology 2009. Hepatol Res. 2011; 41(1): 1–21.
13. Kumada H, Okanoue T, Onji M et al. Study Group for the Standardization of Treatment of Viral Hepatitis Including Cirrhosis, Ministry of Health, Labor and Welfare of Japan. Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis B virus infection for the fiscal year 2008 in Japan. Hepatol Res. 2010; 40(1): 1–7.
14. Fujiyoshi M, Kuno A, Gotoh M et al. Hepatitis Glyco-biomarker Study Group. Clinicopathological characteristics and diagnostic performance of Wisteria floribunda agglutinin positive Mac-2-binding protein as a preoperative serum marker of liver fibrosis in hepatocellular carcinoma. J Gastroenterol 2015; 50(11): 1134–44.
15. Toshima T, Shirabe K, Ikegami T et al. A novel serum marker, glycosylated Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA(+)-M2BP), for assessing liver fibrosis. J Gastroenterol 2015; 50(1): 76–84.
16. Yamasaki K, Tateyama M, Abiru S et al. Elevated serum levels of Wisteria floribunda agglutinin-positive human Mac-2 binding protein predict the development of hepatocellular carcinoma in hepatitis C patients. Hepatology 2014; 60(5): 1563–70.
17. Toyoda H, Kumada T, Tada T et al. Serum WFA+ − M2BP levels as a prognostic factor in patients with early hepatocellular carcinoma undergoing curative resection. Liver Int 2016; 36(2): 293–301.
18. Ura K, Furusyo N, Ogawa E et al. Serum WFA+ − M2BP is a non-invasive liver fibrosis marker that can predict the efficacy of direct-acting anti-viral-based triple therapy for chronic hepatitis C. Aliment Pharmacol Ther 2016; 43(1): 114–24.
19. Nishikawa H, Enomoto H, Iwata Y et al. Clinical significance of serum Wisteria floribunda agglutinin-positive Mac-2-binding protein level and high sensitivity C reactive protein concentration in autoimmune hepatitis. Hepatol Res 2015. doi: 10.1111/hepr.12596.
20. Nishikawa H, Enomoto H, Iwata Y et al. Impact of serum Wisteria floribunda agglutinin-positive Mac-2-binding protein and serum interferon-γ-inducible protein-10 in primary biliary cirrhosis. Hepatol Res 2015. doi: 10.1111/hepr.12595.
21. Abe M, Miyake T, Kuno A et al. Association between Wisteria floribunda agglutinin-positive Mac-2 binding protein and the fibrosis stage of non-alcoholic fatty liver disease. J Gastroenterol 2015; 50(7): 776–84.
22. Kuno A, Ikehara Y, Tanaka Y et al. A serum “sweet-doughnut” 272 protein facilitates fibrosis evaluation and therapy assessment in patients 273 with viral hepatitis. Sci Rep 2013; 3: 1065.
23. Kuno A, Sato T, Shimazaki H et al. Reconstruction of a robust glycodiagnostic agent supported by multiple lectin-assisted glycan profiling. Proteomics Clin Appl 2013; 7(9–10): 642–7.
24. Chen CJ, Yang HI, Su J et al. REVEAL-HBV Study Group. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295(1): 65–73.
25. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50(3): 661–2.
26. Iwata K, Enomoto H, Nishiguchi S et al. Serum zinc value in patients with hepatitis virus-related chronic liver disease: association with the histological degree of liver fibrosis and with the severity of varices in compensated cirrhosis. J Clin Biochem Nutr 2014; 55(2): 147–52.
27. Fernandez M, Trépo E, Degré D et al. Transient elastography using Fibroscan is the most reliable noninvasive method for the diagnosis of advanced fibrosis and cirrhosis in alcoholic liver disease. Eur J Gastroenterol Hepatol 2015; 27(9): 1074–9.
28. Lok AS, McMahon BJ, Brown RS Jr et al. Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis. Hepatology 2016; 63(1): 284–306.
29. Tenney DJ, Rose RE, Baldick CJ et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology 2009; 49: 1503–14.
30. Kwon H, Lok AS. Hepatitis B therapy. Nat Rev Gastroenterol Hepatol 2011; 8(5): 275–84.
31. Aung MN, Leowattana W, Tangpukdee N, Kittitrakul C. Nucleos(t)ide analogues treatment outcome in genotype B and C chronic hepatitis B. N Am J Med Sci 2010; 2(8): 365–70.
32. Feld JJ, Heathcote EJ. Hepatitis B e antigen-positive chronic hepatitis B: natural history and treatment. Semin Liver Dis 2006; 26(2): 116–29.
33. Wandrer F, Falk C, John K et al. Interferon-mediated cytokine induction determines sustained virus control in chronic HCV infection. J Infect Dis 2016; 213(5): 746–54.
34. Nishikawa H, Enomoto H, Nasu A et al. Clinical significance of pretreatment serum interferon-gamma-inducible protein 10 concentrations in chronic hepatitis C patients treated with telaprevir-based triple therapy. Hepatol Res 2014; 44(14): E397–407.
35. Wang CT, Zhang YF, Sun BH et al. Models for predicting hepatitis B e antigen seroconversion in response to interferon-α in chronic hepatitis B patients. World J Gastroenterol 2015; 21(18): 5668–76.